key: cord-0835434-5x1xwyov
authors: Ke, Ruian; Romero-Severson, Ethan; Sanche, Steven; Hengartner, Nick
title: Estimating the reproductive number R(0) of SARS-CoV-2 in the United States and eight European countries and implications for vaccination
date: 2021-02-13
journal: J Theor Biol
DOI: 10.1016/j.jtbi.2021.110621
sha: b1abcaa242c83c3939f89f447217d2e0736f9cbc
doc_id: 835434
cord_uid: 5x1xwyov

SARS-CoV-2 rapidly spread from a regional outbreak to a global pandemic in just a few months. Global research efforts have focused on developing effective vaccines against COVID-19. However, some of the basic epidemiological parameters, such as the exponential epidemic growth rate and the basic reproductive number, R(0), across geographic areas are still not well quantified. Here, we developed and fit a mathematical model to case and death count data collected from the United States and eight European countries during the early epidemic period before broad control measures were implemented. Results show that the early epidemic grew exponentially at rates between 0.18-0.29/day (epidemic doubling times between 2.4-3.9 days). We found that for such rapid epidemic growth, high levels of intervention efforts are necessary, no matter the goal is mitigation or containment. We discuss the current estimates of the mean serial interval, and argue that existing evidence suggests that the interval is between 6-8 days in the absence of active isolation efforts. Using parameters consistent with this range, we estimated the median R(0) value to be 5.8 (confidence interval: 4.7-7.3) in the United States and between 3.6 and 6.1 in the eight European countries. We further analyze how vaccination schedules depend on R(0), the duration of protective immunity to SARS-CoV-2, and show that individual-level heterogeneity in vaccine induced immunity can significantly affect vaccination schedules.

We collected daily case confirmation and death count data from the John Hopkins CSSE 116 (Center for Systems Science and Engineering) database 117 (https://github.com/CSSEGISandData/COVID-19). The data is accessed and extracted on March 118 31, 2020. The data consists of time series of the cumulative number of case confirmations and 119 deaths by country. Daily incidences were derived from the cumulative counts. We included data 120 from the United States (US) and eight most affected European countries where the total deaths 121 exceed 150 by March 31, 2020. The total deaths threshold is to ensure that the number of deaths 122 is high enough for statistical inference. The eight European countries are France (FR), Italy (IT), 123 Spain (SP), Germany (GR), Belgium (BE), Switzerland (SW), Netherlands (NT), United 124 Kingdom (UK). 125 We included a subset of case and death count data for inference based on the two following 126 criteria. First, to minimize the impact of stochasticity and uncertainty in early data collection, we 127 used case confirmation incidence data starting from the date when the cumulative number of 128 cases was greater than 100, and used daily new death count data starting from the date when the 129 cumulative death count is greater than 20 in each country (see Table S1 and Fig. 1 for the period 130 from which data is included). Second, to estimate the early outbreak growth in each country 131 before control measures were implemented, we included case count data up to the date of 132 lockdown in each country. For death counts, we included a maximum of 15 days of data points 133 starting from the date when the cumulative death count is greater than 20 in each country. We 134 tested the sensitivity of model predictions against variations in the number of data points used for 135 inference. In this analysis, we included the 15, 13 or 10 days of data points prior to the date when 136 lockdown was implemented in each country. Overall, we found that the results are consistent 137 across the different numbers of data points used (Table S1) . 138 139 2.2. Model 140

We construct a SEIR type model using ordinary differential equations (ODEs; see 141 Supplementary Text). We consider the exponentially growing phase of the outbreak and thus 142 make the common assumption that the susceptible population is constant over time. Then, the 143 total number of infected individuals can be expressed as:

(1) 144 where is the exponential growth rate of the epidemic (the growth rate for short below), and * 0 145 is the number of total infected individuals at time 0, set arbitrarily as January 20, 2020. Note the 146 choice of the date of time 0 does not affect our estimation. 147 We solve the ODE model and derive the following expressions for the key quantities for 148 model inference (see Supplementary Text). The descriptions and values used for the parameters 149 in the ODE model are summarized in Table 1 . 150 The true daily incidence of infected individuals, , can be expressed as:

(2) 151 where and 1/ are the transmission parameter of the virus and the latent period of infection, 152 respectively. 153

The daily new confirmed case count, , is related to the true daily incidence, as:

154 where is the detection probability, i.e. the fraction of newly individuals at time who are ( ) 155 later detected among all infected individuals. We assumed an Erlang distribution for the period 156 between infection and case confirmation , where and are the mean 1/ 157 and the shape parameter for the distribution. 158

The daily new death count, , is related to the true daily incidence, as:

159 where is the infection fatality ratio. Again, we assumed an Erlang distribution for the period 160 between infection and death , where and are the mean and the shape 1/ 161 parameter for the distribution. 162 We tested three different scenarios for surveillance intensity changes over time, modeled as 163 the detection probability, : 174 We fit the daily case count function and the death count function to incidence data Ψ( ) Φ( ) 175 and daily death data to infer the exponential growth rate of the infection , the initial number ( ) 176 of total infected individuals at time, and the detection probability ( ). Other parameter values 177 are fixed according to previous estimates (see Table 1 ). We assumed that the data were negative 178 binomial distributed conditional on the model and inferred parameters by maximizing the 179 likelihood function using standard methods. 180

To compare between models, we calculate the Akaike Information Criterion (AIC) score for 181 each model as (Burnham and Anderson, 2002):

= 2 -2 (5) 182 where is the number of fitted parameters and LL is the log likelihood of the model. The model 183 with the lowest AIC score is the best model. A model is significantly worse than the best model 184 if the difference between their AIC scores is greater than 2 (Burnham and Anderson, 2002 

197 where and are the mean latent and infectious periods, respectively, and and are the 1/ 1/ 198 shape parameters for the gamma distributions for the latent and the infectious periods, 199 respectively. 200 We set the mean latent period, , to vary between 3 and 4 days. This is based on that the 1/ 201 incubation period is estimated to be between 5-6 days (Backer et al., 2020; Lauer et al., 2020; 202 Sanche et al., 2020) and infected individuals become infectious approximately 2 days before 203 symptom onset . 204 We set the mean infectious period, , to be between 6-8 days to be consistent with the 1/ 205 estimated mean serial interval, i.e. the mean time interval between symptom onsets of an index 206 case and secondary cases in transmission pairs, of 6-8 days (Bi et al., 2020; Lavezzo et al., 2020;  207 Thompson et al., 2020) . See the Discussion section for a discussion of the estimates of the serial 208 interval. We note that this range of infectious period is also consistent with the findings that 209 infectious viruses can be recovered during the first week of symptom onset (and up to 9 days 210 post symptom onset) Wolfel et al., 2020) . 211 To quantify the uncertainty of , we assumed that m=4 and n=3 similar as in our previous 0 212 work . We assume that the exponential growth rate, , varies in the range 213 estimated from the data. The parameters are assumed to be mutually independent and we ( , , ) 214 generate random samples from uniform distributions according to ranges of variations defined 215 above to compute the resulting . We generated parameters, and then computed their 0 10 4 216 respective using Eq. (7). We used the 97.5% and 2.5% percentile of the generated data to 0 217 quantify the 95% confidence interval. 218 219 2.6. Calculation of the level of population immunity after mass vaccination 220

We assume a gamma distribution for the duration of protective immunity induced by a 221 hypothetical vaccine to SARS-CoV-2 in a population. Let be the mean duration, and s be the 222 shape parameter of the gamma distribution. For simplicity, we assume that the durations of the 223 immunity induced by natural infection and vaccination are the same. We further assume that the 224 percentage of protected population reaches to 85% after every mass vaccination with the 225 hypothetical vaccine. Note that this is likely to be an optimistic scenario . The 226 fraction of population that are immune to SARS-CoV-2 at time after a mass vaccination can * 227 then be expressed as , where is the cumulative density function of the 85% × (1 -C( * )) C( * ) 228 gamma distribution for the duration of population immunity. Based on this expression, we 229 calculate the time when the population immunity reaches to the herd immunity threshold value 230 by solving for . The solution for is the maximum time 85% × (1 -C( * )) = 1 -1/ 0 * * 231 interval between two vaccinations to maintain herd immunity in a population. 232 233

234 3.1. Estimation of the epidemic growth rate and surveillance intensity 235 Using our simplified SEIR-type (susceptible-exposed-infected-recovered) model (see 236 Methods and Supplementary Text for details), we fit both the case incidence data and the daily 237 death count data to estimate the epidemic growth rate and the detection probability, i.e. the 238 probability that an infected person is identified, before interventions were implemented in eight 239 European countries and the US. The exponential growth rates of early outbreaks, r, range 240 between 0.19 and 0.29/day in the nine countries, translating to doubling times between 2.4-3.7 241 days (Fig. 1) . Spain and the US had the highest estimated growth rates, at 0.29/day and 0.28/day, 242 respectively; whereas Switzerland and Netherlands had the lowest estimates at 0.19/day and 243 0.18/day, respectively. Evaluating uncertainties in these estimates (see Methods), we found that 244 the epidemic growth rates are highly constrained by the time series data despite variations in 245 parameter values in the model (Fig. 2A) . 246 We estimated that the detection probability, i.e. the fraction of infected individuals who are 247 detected by surveillance, was likely to be low (<30%) across the countries examined except for 248 Germany. The point estimate of the detection probability in the US is 12%, i.e. approximately 1 249 in 8 infected individuals were detected, similar to a recent estimate using influenza like illness 250 data . This is likely due to the high percentage of infected individuals 251 with no or mild-to-moderate symptoms (Mizumoto et al., 2020; Zou et al., 2020) , which are 252 difficult to detect through passive surveillance systems. The detection probability is higher in 253 Germany (with a point estimate of 58%) than in other countries, providing an explanation of the 254 high number of reported cases compared to the relative low number of deaths in Germany during 255 March 2020. Overall, there exist large uncertainties in our estimation of the detection probability 256 (Fig. S1 ) due to the uncertainties in the fixed parameter values assumed in the model, such as the 257 infection fatality ratio. 258

Changes to the detection probability over time, e.g. as a result of changes in testing, could 259 lead to an apparent increase or decrease in case count and biases in inference. We considered two 260 scenarios involving increases in testing over the study period (see Methods for the mathematical 261 formulations), and found no statistical evidence that case counts during the relatively short 262 period for which we perform inference are strongly impacted by changes in surveillance intensity 263 (Table S2 ). While it is highly likely that the probability of a case being detected increased over 264 the period where testing was becoming available, our analysis excluded data from that period. As 265 shown in Fig. 1 , the red, open circles indicate data outside of the study period. Most countries 266 show a pattern of very rapid increase in detected cases in the very early epidemic period that is 267 likely the result of both a growing epidemic and increasing availability and use of testing. 268 269 3.2. Implications of fast epidemic growth for public health intervention strategies 270

Using our empirical estimates of the growth rates, we explored the implications for public 271 health efforts to control the COVID-19 outbreak. We considered an outbreak scenario in a large 272 city with a population of 10 million. We first calculated the total fraction of infected individuals 273 after a year, assuming only one infected individual at day 0. If our goal is that the total fraction 274 of infected individuals is less than 10% after a year, the growth rate has to be reduced from 0.2-275 0.3/day to less than 0.03/day (Fig. 2B ). This suggests that moderate social distancing efforts will 276 be insufficient to prevent the virus to infect a large fraction of the populatino. On the other hand, 277 if the targeted growth rate, i.e. 0.03/day, is achieved through very strong public health 278 interventions, then a lower rate may also be attainable. The benefits of a small decrease below 279 the threshold are significant, as the total infected fraction decreases exponentially when r 280 decreases beyond 0.03/day as shown in Fig. 2B . 281

To corroborate the results above, we calculated the intervention efforts needed for three 282 hypothetical goals: 1) containment (i.e. the size of epidemic decreases), 2) 1% of the population 283 is infected one year after the intervention, and 3) 10% of the population is infected one year after 284 the intervention. Efforts needed for each goal are similarly high, especially when the population 285 of infected individuals is already more than 1000 (Fig. 2C) . For example, when an outbreak 286 grows at rate 0.29/day (as we estimated for the US), the levels of efforts needed to achieve the 287 three goals are between 80% and 82% reduction in transmission; whereas when the growth rate 288 is 0.19/day, the levels of effort needed are between 70% and 73% reduction. Regardless of the 289 heterogeneity in the growth rates, the force of infection must be significantly reduced, arguing 290 for strong and comprehensive intervention efforts. 291 292 3.3. Estimating the basic reproductive number, R 0 293

We computed the basic reproductive number, R 0 , for each country following the approach of 294 Wearing et al. (Wearing et al., 2005) , which uses as input the estimated growth rate, and the 295 durations of the latent and infectious periods. We assumed that the duration of the latent period 296 (i.e. the period between infection and becoming infectious) and the infectious periods to be 3-4 297 days and 6-8 days, respectively (see Methods for justification of these parameter ranges). These 298 choices of parameters are consistent with the estimated mean serial intervals of 6-8 days (Bi et 299 al., 2020; Lavezzo et al., 2020; Thompson et al., 2020) . Note that some estimates of the mean 300 serial intervals are shorter (Du et al., 2020; Ganyani et al., 2020; Nishiura et al., 301 2020) . These shorter serial intervals are a result of intensive intervention efforts to rapidly isolate 302 infected individuals (Ali et al., 2020; Bi et al., 2020) , and can be useful in estimating effective 303 reproductive numbers in places where intensive isolation efforts are implemented. However, for 304 the purpose of estimating the basic reproductive number, R 0 , and the herd immunity threshold (in 305 the next section), the mean serial interval in the absence of isolation effort, i.e. 6-8 days, shall be 306 used. In the Discussion, we present a more complete argument that for the choice of the duration 307 of the mean serial interval. 308

Using the estimated ranges of the growth rates for each country, we estimated that the US 309 and Spain had highest median R 0 s at 5.9 (CI: 4.7-7.5) and 6.4 (5.2-8.0), respectively ( Fig. 3 and 310 Table 2 ). For the other countries, we estimated the median R 0 ranges between 3.5 and 4.7 (Fig. 3  311 and Table 2 ). 312 313 3.4. Implications for vaccination strategies 314

From the range of median R 0 estimated above, we first calculated the fraction of individuals 315 needed to be immune in a homogenous population such that an outbreak stops growing. This 316 fraction is given by the classical result, 1-1/R 0 . We refer to this term 317 as the 'classical herd immunity threshold', which spanned between 71% and 84% for the 318 countries considered here (Table 2) . We note that recent works show that due to population 319 heterogeneity, the herd immunity threshold induced by disease transmission may be lower than 320 the classical threshold predicted by 1-1/R 0 (Britton et al., 2020; Gomes et al., 2020). However, 321 the herd immunity threshold through random vaccination stays at 1-1/R 0 . 322

Multiple lines of evidence suggest that the protective immunity may not be long lived for 323 SARS-CoV-2 (Long et al., 2020; Seow et al., 2020). Thus, we further considered how a vaccine 324 with waning protection could be used to combat COVID-19 given our estimated levels of R 0 (see 325 Method). We assumed that vaccination achieves 85% population immunity in a population. This 326 is an optimistic scenario. For example, with a protective efficacy of 94%, the coverage has to be 327 greater than 90% to achieve 85% population immunity. If this level of immunity is not achieved, 328 for example, due to low vaccination coverage or low protective efficacy, we 329 may not reach herd immunity through vaccination for places where R 0 is estimated to be around 330 6, e.g. the US and Spain. In the model, we assumed a gamma distribution for the duration of 331 protective immunity induced by a hypothetical vaccine in a population, where s is the shape 332 parameter of the gamma distribution (Fig. 4A) . 333 If the duration of protective immunity from the vaccine follows an exponential distribution, 334 (i.e. when ), a sizable fraction of individuals lose immunity rapidly, leading to a loss of = 1 335 herd immunity shortly after the initial vaccination program, especially when R 0 is large and the 336 herd immunity threshold is high (Fig. 4B) . Consequently, the time between vaccinations required 337 to maintain herd immunity is much shorter than the mean duration of protective immunity (Fig.  338 4C) . For example, even if the mean duration of protective immunity is 10 years, vaccination 339 must occur every 2.4 month and 2.4 years to maintain herd immunity when R 0 is 6 and 3, 340 respectively (see the red lines in Fig. 4C ). On the other extreme, when s is very large (Fig. 4A,  341 ), individuals in the population have identical durations of protective immunity. In this = ∞ 342 case, herd immunity persists for a long period of time before the fraction of immune individuals 343 suddenly drops to a very low level (Fig. 4B) . In this case, herd immunity can be kept at a 344 duration similar to the mean duration of protective immunity irrespective of R 0 (see blue lines in 345 Fig. 4C ). 346

The reality of an imperfect vaccine is likely to be between these two extremes. When we 347 assume , the distribution becomes more Gaussian-like (Fig. 4A) where some people lose = 10 348 protective immunity faster than others, but that heterogeneity is relatively low. If a mass 349 vaccination achieves 85% immunity in a population and protective immunity lasts on-average 350 around 45 weeks to 1 year (Long et al., 2020) (consistent with the duration of immunity induced 351 by endemic coronaviruses (Callow et al., 1990; Kissler et al., 2020) ), then vaccination will need 352 to occur once a few months (Fig. 4C ). If the mean duration of protective immunity is around 3 353 years as observed for the antibody response to SARS-CoV-1 or MERS-CoV , 354 vaccination once a year or once two years will be sufficient, if R 0 is 6 or 3, respectively (Fig. 4C) . 355 If the mean duration of protective immunity is greater than 10 years (for example, a long T cell 356 immunity to SARS-CoV-1 is observed in individuals recovered from SARS-CoV-1 infection (Le 357 Bert et al., 2020)), the time interval between repeated vaccinations becomes longer than 4 years 358 or 7 years when R 0 is 6 or 3, respectively. 359 360

In this work, we report rapid COVID-19 epidemic spread before broad control measures 362 were implemented in the US and in the eight most affected countries in Europe during March, 363 2020. We further estimated that R 0 values range between 3.5 and 6.4 in these countries, which 364 means high herd immunity thresholds between 71% and 84%. Together with our previous 365 estimates for the outbreak in Wuhan , these results are consistent with 366 SARS-CoV-2 being highly transmissible irrespective of heterogeneities in geographic and social 367 settings and emphasize the necessity of strong control measures, such as social distancing. A 368 high level of coverage of effective vaccines are needed to achieve herd immunity. We further 369 show that the heterogeneity of individual-level protection provided by a vaccine is an important 370 factor in determining the frequency of vaccinations. 371

Awareness of the extraordinary high rates of COVID-19 spread in the absence of control 372 measures is critically important for epidemic preparedness. The short doubling times of the 373 epidemic means that health care systems can be overwhelmed in a couple of weeks rather than 374 several months in the absence of control . For example, a report shows that the 375 number of COVID-19 patients admitted to intensive care units in Italy during February and early 376 March 2020 grew at a rate of approximately 0.25/day during early epidemic (Grasselli et al., 377 2020) . We estimated that the SARS-CoV-2 outbreaks grew extremely rapidly at rates between 378 0.18 and 0.29/day, in eight European countries and the US. These estimates for European 379 countries are in general consistent with other studies using different approaches and different 380 sources of data (Dehning et al., 2020; Flaxman et al., 2020; Pellis et al., 2020). We further show 381 that because of the high transmissibility of the virus, moderate control efforts will not 382 sufficiently slow the virus spread to achieve measurable public health benefits. This may explain 383 the continuous growth of the outbreak in some countries despite measures, such as work and 384 school closures, were in place. To delay the peak or to reverse the growth of the epidemic with 385 non-pharmaceutical interventions, strong and comprehensive intervention efforts, such as wide-386 spread testing, isolation and quarantine, use of personal protective equipment, and social 387 distancing, may be needed. 388

While we found remarkably high rates of epidemic growth in all the examined countries, we 389 caution that our inference is largely driven by data collected from highly populated areas, such as cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. interventions. Science 369, doi:10.1126/science.abb9789. 520 Dorigatti, I., Okell, L., Cori, A., Imai, N., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z., 521

Cuomo-Dannenburg, G., FitzJohn, R., al., e., Xi, X., Donnelly, C., Ghani, A., Neil, F., 522 2020. Severity of 2019-novel coronavirus (nCoV). 523

(https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-524 fellowships/Imperial-College-COVID19-severity-10-02-2020.pdf; accessed Mar 30, 525 2020). 

2020b) and potential health and 71 economic damage. They set the baseline for evaluation of effectiveness of country specific 72 public health intervention strategies

Initial estimates of the rate of early epidemic spread in Wuhan, China suggested that the

However, using domestic 80 travel data and two distinct approaches, we estimated that the epidemic in Wuhan grew much

Lombardy in Italy, and New York city in the US. Heterogeneities in the growth 391 rate almost certainly exist among different areas within each country. For example, recent works 392 suggest that the rate of spread is positively associated with population densities

One limitation of our inference (as well as in other works

In addition, factors 403 including changes in definitions and protocols for ascertaining COVID deaths, updating prior 404 deaths may also impact on COVID death reporting. 405 Calculation of the basic reproductive number requires knowledge of the distribution of the 406 length of serial interval (SI)

2020), we assumed parameter values that are 408 consistent with a mean SI of 6-8 days

This 410 led to higher estimates of R 0 for the European countries than other studies

However, Bi et al. demonstrated that when the 413 transmission pair is not isolated rapidly after symptom onset, the mean serial interval is 414 estimated to be 8 days

However, these estimates were 418 based on data reported in locations outside of Wuhan, Hubei province, and other Asian countries 419 and territories neighboring China, and thus were strongly impacted by active surveillance and 420 isolation effort as demonstrated by

We calculated the classical herd immunity thresholds 1-1/R 0 , derived from models assuming 430 a homogenous population

Other intervention efforts including both non-pharmaceutical, 438 i.e. effective test, trace and isolation, and pharmaceutical interventions, i.e. therapeutics, are 439 likely needed in addition to vaccination. If the herd immunity threshold is not achieved, i.e. a 440 likely scenario given the high herd immunity thresholds

We note that the herd immunity thresholds derived from the classical formula, 1-1/R 0 , such as age structure and contact activity levels (Britton et al., 2020), and individual 446 susceptibility and exposure

Recent COVID-19 vaccine trials show that they are highly efficacious in preventing disease 455 (Moderna, 2020; Pfizer, 2020); refs

individuals, such as Refs

Overall, our work shows that SARS-CoV-2 has high R 0 values and spread very rapidly in the

We would like to thank Alan Perelson for suggestions and critical reading of the manuscript

The work is partially funded by the Laboratory Directed Research and Development (LDRD)

SS would like to acknowledge funding from DARPA (HR0011938513) and 479 the Center for Nonlinear Studies. ERS was funded through the NIH grant (R01AI135946)

Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical 485 interventions

Infectious Diseases of Humans: Dynamics and Control

489 Heterogeneity and longevity of antibody memory to viruses and vaccines

Incubation period of 2019 novel coronavirus 492 (2019-nCoV) infections among travellers from Wuhan, China

2020. A quantitative 495 compendium of COVID-19 epidemiology

Epidemiology and transmission of COVID-19 in 391

Serial interval of 527 COVID-19 among publicly reported confirmed cases

Estimating the effects of non

535 Estimating the generation interval for coronavirus disease (COVID-19) based on 536 symptom onset data

Individual 540 variation in susceptibility or exposure to SARS-CoV-2 lowers the herd immunity 541 threshold. medRxiv

Critical care utilization for the COVID-19 outbreak 543 in Lombardy, Italy: early experience and forecast during an emergency response

Temporal dynamics in 548 viral shedding and transmissibility of COVID-19

An 556 mRNA vaccine against SARS-CoV-2 -preliminary report

Fast spread of COVID-19 in 559 Europe and the US suggests the necessity of early, strong and comprehensive 560 interventions. medRxiv

Projecting the 562 transmission dynamics of SARS-CoV-2 through the postpandemic period

565 SARS-CoV-2 detection in patients with influenza-like illness

568 Centre for Mathematical Modelling of Infectious Diseases, C.-w. g., 2020. Early 569 dynamics of transmission and control of COVID-19: a mathematical modelling study

The incubation period of coronavirus disease 2019 573 (COVID-19) from publicly reported confirmed cases: estimation and application

Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'

Immunological characteristics govern the 585 transition of COVID-19 to endemicity

SARS-CoV-589 2-specific T cell immunity in cases of COVID-19 and SARS

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected 597 pneumonia

Estimated demand for 599 US hospital inpatient and intensive care unit beds for patients with COVID-19 based on 600 comparisons with Wuhan and Guangzhou, China

Substantial 603 undocumented infection facilitates the rapid dissemination of novel coronavirus

CoV-2)

Transmission dynamics 607 and control of severe acute respiratory syndrome

Clinical and immunological assessment of asymptomatic SARS

CoV-2 infections

Ensuring uptake of vaccines against SARS-614

Estimating the asymptomatic 616 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond 617 Princess cruise ship

Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy 620 Endpoint in the First Interim Analysis of the Phase 3 COVE Study

Evaluation of the effectiveness of surveillance and 625 containment measures for the first 100 patients with COVID-19 in Singapore

Serial interval of novel coronavirus 629 (COVID-19) infections

Reconciling early-outbreak estimates of the basic reproductive number 632 and its uncertainty: framework and applications to the novel coronavirus (SARS-CoV-2) 633 outbreak. medRxiv

Challenges in control of Covid-19: 641 short doubling time and long delay to effect of interventions. medRxiv

PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 644 VACCINE CANDIDATE

Crowding and 649 the epidemic intensity of COVID-19 transmission. medRxiv

Pattern of early human-to-human transmission of Wuhan

Change in global 655 transmission rates of COVID-19 through

Estimating the burden of SARS

CoV-2 in France

High 662 Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

670 Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. 671 medRxiv

Using influenza surveillance networks to 673 estimate state-specific prevalence of SARS-CoV-2 in the United States

Estimation of the 676 Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions

Key questions for modelling COVID-19 exit strategies

Appropriate models for the management of 688 infectious diseases

WHO, 2020. Pneumonia of unknown cause -China

Virological 694 assessment of hospitalized patients with COVID-2019

Nowcasting and forecasting the potential domestic 697 and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 698 modelling study

Estimating clinical severity of COVID-19 from the 701 transmission dynamics in Wuhan, China

Clinical 705 course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: 706 a retrospective cohort study

SARS-CoV-2 viral load in 709 upper respiratory specimens of infected patients

A) and the 730 detection probability, (B) in each country. See Table 2 for country name abbreations. (C) High 731 levels of control efforts, measured as fractions of transmission reduction (y-axis), are needed to 732 achieve containment, i.e. reverting epidemic growth (dots), or mitigation, i.e. the final fraction of population. (A) Three scenarios for the distribution: 746 exponential

 Tables   759  760  761 Table 1 

 The median R 0 value is 5.8 in the US and between 3.6 and 6.1 in other countries.

 The herd immunity thresholds are between 71% and 84%.

 Individual heterogeneity in protective immunity affects vaccination schedules. 777